Immunethep discovered a novel mechanism used by different pathogenic bacteria to suppress host immune response. By targeting this mechanism, the company is developing broad coverage anti-bacterial Immunotherapies. Its first product is a Paragon Novel Vaccine (PNV) that is able to address multiple bacterial strains (E. coli, K. pneumoniae, S. aureus, S. pneumoniae and S. agalactiae), it is all valent (full serotype coverage), Microbiome friendly and is addressed to all population.

One pager